What's Happening?
Researchers at Weill Cornell Medicine have discovered a common genetic vulnerability across various cancer types and are developing drug compounds to exploit it. The new strategy targets the WNT signaling pathway, which is often hyperactive in cancers
and contributes to malignancy. Historically, targeting WNT signaling without harming healthy cells has been difficult. However, the study, published in Nature Chemical Biology, found that many cancer cells are deficient in one of two redundant WNT-supporting enzymes, TNKS1 and TNKS2. By selectively inhibiting the remaining enzyme, TNKS2, researchers observed a reduction in WNT signaling in these cancer cells without affecting healthy cells. Early preclinical experiments with a selective TNKS2 inhibitor have shown success in suppressing the growth of cancer cells with partial or full TNKS1 loss. This approach could lead to a potent treatment with fewer side effects for patients with colorectal, breast, and other cancer types.
Why It's Important?
This discovery holds significant importance for cancer treatment in the U.S. and globally, offering a potential breakthrough in targeted therapies. The WNT pathway's hyperactivity is implicated in a wide range of cancers, including nearly all colorectal cancers and over half of breast cancers, alongside substantial proportions of liver, lung, prostate, skin, bone, and gynecologic cancers. The ability to selectively target cancerous cells while sparing healthy ones could drastically reduce the severe side effects associated with current cancer treatments, improving patient quality of life and treatment adherence. This research could lead to the development of a new class of drugs, potentially transforming treatment protocols for millions of cancer patients and creating new opportunities within the pharmaceutical industry for drug development and commercialization.
What's Next?
The Dow lab plans to develop a next-generation compound with improved drug-like properties, utilizing detailed structural models of TNKS1 and TNKS2. If this compound performs well in comprehensive preclinical tests, the researchers aim to advance it into clinical trials. The goal is to overcome the long-standing challenge of targeting the WNT pathway in cancer without causing significant side effects. The progression to clinical trials would involve rigorous testing in human subjects to confirm efficacy and safety, a process that could take several years. Successful trials could pave the way for regulatory approval and eventual availability of the new treatment to patients, potentially reshaping cancer therapy paradigms.
Beyond the Headlines
The underlying principle of exploiting specific genetic vulnerabilities in cancer cells, rather than broadly attacking rapidly dividing cells, represents a significant shift in oncology. This precision medicine approach aligns with a growing trend in healthcare to tailor treatments to individual patient profiles, minimizing harm and maximizing effectiveness. The research also highlights the importance of understanding the intricate genetic landscape of tumors, as seemingly minor genetic deletions (like that of TNKS1) can create critical therapeutic windows. This could encourage further research into identifying similar 'hidden vulnerabilities' in other diseases, fostering a new era of highly specific and less toxic therapeutic interventions.
